· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffmann-La Roche Ltd.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
December 7, 2011
Subject: Reports of cases of severe eye inflammation leading to blindness following the unauthorized use of AVASTIN® (bevacizumab) in the eye
Hoffmann-La Roche Limited (Roche), in consultation with Health Canada, has informed Canadian healthcare providers of important new safety information regarding the unauthorized use of AVASTIN® (bevacizumab) when injected into the eye.
A previous For Health Professionals communication and For the Public communication were issued in 2008.
About AVASTIN
AVASTIN is packaged into single-use, sterile, preservative-free vials to treat cancer by injection into the veins. The practice of repackaging single-use AVASTIN vials into several syringes may contaminate the product.
AVASTIN is authorized, in combination with chemotherapy, for the treatment of people diagnosed with:
In addition, AVASTIN is authorized as a single agent for a particular type of brain cancer called glioblastoma (this use has conditions required by Health Canada).
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving AVASTIN should be reported to Hoffmann-La Roche Limited or Health Canada at the following addresses:
Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction and Medical Device Problem Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of AVASTIN, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388, Monday to Friday, between 8:30 a.m. and 4:30 p.m. (Eastern Standard Time).
Sincerely,
original signed by
Lorenzo Biondi
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited